Options for Program Chemotherapy and Their Outcomes in Patients with Newly Diagnosed Mantle Cell Lymphoma Based on the Data from a Single Center
Authors:
- Ulyana Gordeevna KoshkinaUKUlyana Gordeevna Koshkina
- G. S. TumyanGTG. S. Tumyan
- A. A. SemenovaASA. A. Semenova
- M. Yu. KichiginaMKM. Yu. Kichigina
- I. Z. ZavodnovaIZI. Z. Zavodnova
- D. N. TupitsynaDTD. N. Tupitsyna
- E. V. ParamonovaEPE. V. Paramonova
- A. S. AntipovaAAA. S. Antipova
- V. O. ShpirkoVSV. O. Shpirko
- S. F. RamazanovaSRS. F. Ramazanova
- A. V. ArakelyanAAA. V. Arakelyan
Open Access
- 1 April 2025
- journal article
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (2) , 121-133
Abstract
AIM. To assess the clinical characteristics and efficacy of chemotherapy for patients with newly diagnosed mantle cell lymphoma (MCL) based on the data from a single center. MATERIALS & METHODS. The study enrolled 60 MCL patients treated at the NN Blokhin National Medical Cancer Research Center from 2008 to 2024. The patients were 37–79 years of age (median 58 years); there were 22 women and 38 men. According to MIPI, there were 18 (30 %) low risk, 22 (37 %) intermediate risk, and 20 (33 %) high risk patients. Intensified regimens with high-dose cytarabine were administered to 31 (52 %) patients, whereas standard non-intensified R-CHOP, R-B, R-BAC and similar regimens were used in 29 (48 %) patients. Autologous hematopoietic stem cell transplantation (auto-HSCT) was performed in 18 (30 %) patients after completing 6 cycles of induction immunochemotherapy. Maintenance rituximab therapy was assigned to 36 (60 %) patients. Ibrutinib, one of Bruton’s tyrosine kinase inhibitors, was added to basic immunochemotherapy in 11 (18 %) patients. RESULTS. The 3-year progression-free survival (PFS) of the recipients of intensified regimens with high-dose cytarabine was 73 % vs. 54 % (p < 0.05) shown by the recipients of the above listed standard non-intensified treatment protocols. The 3-year PFS of elderly recipients of bendamustine-based treatment was 64 % vs. 25 % shown by the patients treated with R-CHOP/R-CHOP-like regiments (p = 0.05). The 3-year PFS of recipients and non-recipients of maintenance rituximab therapy was 86 % and 33 %, respectively (p = 0.001). In the groups of recipients and non-recipients of auto-HSCT, it was reported to be 76 % and 56 % (p = 0.05). In the total group (n = 60), with the follow-up median of 36 months, the 3-year PFS was 64 % (median 54 months), and the 3-year OS was 80 % (median 84 months). The 3-year PFS rates in MCL patients varied considerably at different historic stages and were 42 % during the period from 2008 to 2017 and 86 % from 2018 to 2024 (p = 0.02). CONCLUSION. The present study covers the period of 16 years characterized by changing approaches to MCL treatment. The 3-year PFS rate of 86 % in the period of 2018–2024 increased nearly twofold compared to 2008–2017. Intensified program MCL first-line therapy with high-dose cytarabine significantly improves the long-term outcomes as opposed to standard immunochemotherapy (R-CHOP, R-B, etc.). For elderly MCL patients, bendamustine-based regimens appear to be most effective. Irrespective of patient’s age, it should be recognized that ibrutinib added to basic MCL chemotherapy holds the most promise. Maintenance rituximab therapy is a must in program treatment. Consolidation auto-HSCT performed after basic immunochemotherapy is associated with higher rates of long-term survival. The present study yielded results comparable to international data and showing a high reproducibility in real-world clinical practice.Keywords
This publication has 30 references indexed in Scilit:
- Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkThe Lancet, 2024
- Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trialThe Lancet Oncology, 2022
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaNew England Journal of Medicine, 2018
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialThe Lancet, 2018
- Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell LymphomaNew England Journal of Medicine, 2017
- Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkThe Lancet, 2016
- Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell LymphomaNew England Journal of Medicine, 2015
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004Cancer, 2008
- From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decadesHuman Pathology, 2002